SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer
12 references·0 citing·43 second hop
Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer (2012)Assessing the Real-World Cost-Effectivene…Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)Using Effectiveness and Cost-…Health related quality of life in different states of breast cancer (2007)Health related quality of lif…Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2007)Cost Effectiveness of Adjuvan…A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)A Cost-Effectiveness Analysis…Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis (2006)Trastuzumab in adjuvant breas…Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra (2005)Probabilistic sensitivity ana…Probabilistic Sensitivity Analysis for Decision Trees with Multiple Branches: Use of the Dirichlet Distribution in a Bayesian Framework (2003)Probabilistic Sensitivity Ana…Systematic Overview of Cost-Utility Assessments in Oncology (2000)Systematic Overview of Cost-U…A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast Cancer (1996)A New Decision Model for Cost…A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer (1996)A Cost-Utility Analysis of Se…Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer (1992)Efficacy and Cost-effectivene…Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer (1991)Efficacy and Cost Effectivene…EuroQol - a new facility for the measurement of health-related quality of life (1990)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Health Care Economic Analyses and Value-Based Medicine (2003)HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)Health Utilities Using the EQ-5D in Studies of Cancer (2007)Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Attributes and weights in health care priority setting: A systematic review of what counts and to what extent (2015)Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)The Combination of Estimates from Different Experiments (1954)Utility approach to measuring health-related quality of life (1987)Health and Economic Outcomes Modeling Practices: A Suggested Framework (1998)Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK (2001)Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study (2004)The Markov Process in Medical Prognosis (1983)A Clinician's Guide to Cost-Effectiveness Analysis (1990)Setting Health Care Priorities in Oregon (1991)Cost-effectiveness of captopril therapy after myocardial infarction (1995)Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)Markov Models in Medical Decision Making (1993)Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms (2007)Uncertainty and Patient Heterogeneity in Medical Decision Models (2010)Cost of anxiety disorders in Japan in 2008: a prevalence-based approach (2013)Cost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Health-state utility values in breast cancer (2010)What Patients Can Tell Us: Topic Analysis for Social Media on Breast Cancer (2017)Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare (2018)Optimistic Biases About Personal Risks (1989)Assessment of quality of life in clinical trials (1991)Cost-utility in practice: A policy maker's guide to the state of the art (1992)Clinical decision analysis (2005)Costs, effects and C/E‐ratios alongside a clinical trial (1994)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)Whither trial‐based economic evaluation for health care decision making? (2006)Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias (2009)Evidence Synthesis for Decision Making 2 (2012)The Beaver Dam Health Outcomes study (1993)Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? (2008)Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer (2007)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer (2015)
this work references cited by second hop

References

  • 2005Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra472 cited
  • 2009Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions343 cited
  • 2000Systematic Overview of Cost-Utility Assessments in Oncology296 cited
  • 1991Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer237 cited
  • 2007Health related quality of life in different states of breast cancer224 cited
  • 2003Probabilistic Sensitivity Analysis for Decision Trees with Multiple Branches: Use of the Dirichlet Distribution in a Bayesian Framework194 cited
  • 2007Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer140 cited
  • 1992Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer139 cited
  • 2007A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer119 cited
  • 1996A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast Cancer96 cited
  • 1996A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer93 cited
  • 2006Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis48 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work